Latest Health Insurance News

Emyria Limited reports that approximately 67% of patients treated for PTSD remain in remission over 12 months post-treatment, highlighting the potential for lasting recovery and cost-effective care.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

Proteomics International secures a key Medicare reimbursement rate for its PromarkerD test, a predictive diagnostic for diabetic kidney disease, marking a critical step in its US commercial rollout.

Medibank has set ambitious goals to triple its health segment earnings by FY30, expand its private health insurance market share, and double its health engagement, signaling a strategic pivot towards integrated, technology-driven care.

Emyria reports strong revenue growth driven by expanded insurer-funded mental health programs, marking a significant step in national access to evidence-based PTSD and treatment-resistant depression care.

Credit Clear Limited has agreed to acquire UK debt collector ARC Europe for A$10.9 million, backed by a $20.75 million institutional placement led by Chair Paul Dwyer. The deal aims to accelerate growth by integrating Credit Clear’s digital platform into ARC’s established UK operations.

ImpediMed secures expanded insurance reimbursement for its SOZO platform, now covering over 301 million US lives and enhancing early detection of breast cancer-related lymphedema.

NIB Holdings Limited has updated its dividend details, declaring a fully franked ordinary dividend of AUD 0.16 per share for the first half of FY2025 and revising the Dividend Reinvestment Plan price to AUD 7.5154.

Emyria secures a multi-year funding agreement with Medibank to support its Treatment-Resistant Depression program, marking a first for insurer-backed psychotherapy in Australia.

Visionflex Group Limited’s FY25 results highlight a strong transition to a SaaS-driven model, with recurring revenue surging 49% to $1.9 million and total revenue up 33%. Key government and private sector contracts underpin future growth prospects.

NobleOak Life Limited reported a robust 20% growth in in-force premiums and a 22% rise in underlying profit for FY25, surpassing guidance and setting a clear path to $1 billion in-force premium. Strategic partnerships, acquisitions, and product innovation underpin its strong outlook for FY26.